{"filing":{"accession_number":"0001193125-26-253478","cik":"0001806310","ticker":"TSHA","company_name":"Taysha Gene Therapies, Inc.","form":"8-K","filing_date":"2026-06-02","report_date":null,"primary_document":"d159199d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312526253478/d159199d8k.htm"},"events":[{"id":7461,"run_id":6557,"accession_number":"0001193125-26-253478","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of Taysha Gene Therapies' 2026 annual meeting of stockholders held on June 1, 2026. The filing presents voting results for four proposals: election of two directors (Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D.), ratification of Deloitte \u0026 Touche LLP as auditor, advisory approval of named executive officer compensation, and advisory frequency vote on future compensation votes. All proposals passed with substantial majorities, and the Board has determined to solicit advisory votes annually based on stockholder preference.","company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","filing_date":"2026-06-02","form":"8-K","submitted_at":null,"items":[{"id":3574,"accession_number":"0001193125-26-253478","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Taysha Gene Therapies' 2026 annual meeting of stockholders held on June 1, 2026. The filing presents voting results for four proposals: election of two directors (Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D.), ratification of Deloitte \u0026 Touche LLP as auditor, advisory approval of named executive officer compensation, and advisory frequency vote on future compensation votes. All proposals passed with substantial majorities, and the Board has determined to solicit advisory votes annually based on stockholder preference.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:17:20.688836+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3574,"accession_number":"0001193125-26-253478","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of Taysha Gene Therapies' 2026 annual meeting of stockholders held on June 1, 2026. The filing presents voting results for four proposals: election of two directors (Sean P. Nolan and Laura Sepp-Lorenzino, Ph.D.), ratification of Deloitte \u0026 Touche LLP as auditor, advisory approval of named executive officer compensation, and advisory frequency vote on future compensation votes. All proposals passed with substantial majorities, and the Board has determined to solicit advisory votes annually based on stockholder preference.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-03T02:17:20.688836+00:00","company_name":"Taysha Gene Therapies, Inc.","ticker":"TSHA","filing_date":"2026-06-02"}]}